The company has signed accords with PharmaMar (Madrid), to identify clinical markers for tracking anti-tumor agents, and Dyax Corp (USA), to develop therapeutic antibodies.
As if it were a social network, the new technology developed by Anaxomics can integrate all the information that is known on biological networks and mechanisms of action of medicines.
Raphael Klingmann and Dariusch Mani, two executives with extensive international pharmaceutical industry experience, have joined the company's management team.
It is based on Membrane Lipid Therapy (MLT), which alters the dynamics of multiple cell membrane proteins. The company is seeking new investors in order to proceed with preclinical development.
The new center has required a total investment of 40 million euros. The products manufactured there, active pharmaceutical ingredients, will be sold on the American, European, Japanese and Chinese markets.
Sagetis is working on technology to allow for drug delivery through the blood-brain barrier (BBB), opening the door to treatment for diseases that currently have no cure.
